Unknown

Dataset Information

0

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.


ABSTRACT: Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.

SUBMITTER: Stone RM 

PROVIDER: S-EPMC3023007 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

Stone Richard M RM   Moser Barry B   Sanford Ben B   Schulman Philip P   Kolitz Jonathan E JE   Allen Steven S   Stock Wendy W   Galinsky Ilene I   Vij Ravi R   Marcucci Guido G   Hurd David D   Larson Richard A RA  

Leukemia research 20100804 3


Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen  ...[more]

Similar Datasets

| S-EPMC6312035 | biostudies-literature
| S-EPMC9327534 | biostudies-literature
| S-EPMC5004463 | biostudies-literature
| S-EPMC8580622 | biostudies-literature
| S-EPMC7289527 | biostudies-literature
| S-EPMC6661897 | biostudies-literature
| S-EPMC8469571 | biostudies-literature
| S-EPMC3683663 | biostudies-literature
| S-EPMC7460695 | biostudies-literature
| S-EPMC6119144 | biostudies-literature